# US 11,896,558 B2 · Use of an RXR agonist and taxanes in treating Her2+ cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,896,558 B2
- Document ID: US11896558B2
- Status: Granted
- Kind: B2
- Application number: 18/076,992
- Filed: 2022-12-07
- Published: 2023-06-08
- Granted: 2024-02-13
- Earliest claimed: 2021-12-07
- Assignees: Io Therapeutics, Inc.; Board of Regents, The University of Texas System
- Applicants: Io Therapeutics, Inc.; Board of Regents, The University of Texas System
- Inventors: Martin E. Sanders; Powel H. Brown; Cassandra Moyer; Abhijit Mazumdar
- Web page: https://patentgrep.com/patent/US11896558B2

## CPC

- A61K 31/015: carbocyclic
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present specification provides improved methods of treating Her2+ cancers in which an RXR agonist and a taxane are administered to a subject having a Her2+ cancer. Thyroid hormone and other anticancer agents may also be administered. Related compositions and combination are also disclosed.

## Claims

### Claim 1

A method of treating a Her2+ cancer in a patient in need thereof comprising administering a taxane and a RXR agonist of Formula I,
wherein R is H, or lower alkyl of 1 to 6 carbons, or a pharmaceutically-acceptable salt thereof, to the patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient had previously been treated with a taxane but not with the RXR agonist and had obtained less than a complete response.

### Claim 3 (depends on 1)

The method of claim 1, wherein the patient had previously been treated with the RXR agonist, but not the taxane.

### Claim 4 (depends on 1)

The method of claim 1, further comprising administering thyroid hormone.

### Claim 5 (depends on 1)

The method of claim 1, wherein the RXR agonist is the compound of Formula II:

### Claim 6 (depends on 1)

The method of claim 1, wherein the taxane is paclitaxel.

### Claim 7 (depends on 1)

The method of claim 1, wherein the taxane is docetaxel.

### Claim 8 (depends on 1)

The method of claim 1, wherein the Her2+ cancer is gastroesophageal cancer, ovarian cancer, stomach cancer, adenocarcinoma of the lung, uterine cancer, or salivary duct carcinoma.

### Claim 9 (depends on 1)

The method of claim 1, wherein the Her2+ cancer is breast cancer.

### Claim 10 (depends on 1)

The method of claim 1, wherein the combination of the taxane and the RXR agonist has a growth inhibitory effect that is greater than the additive growth inhibitory effects of each of the two agents alone.

### Claim 11 (depends on 1)

The method of claim 1, further comprising administration of an additional anticancer agent.